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Background: Autism spectrum disorder (ASD) is characterized by three core behavioral domains: social deficits,
impaired communication, and repetitive behaviors. Glutamatergic/GABAergic imbalance has been found in various
preclinical models of ASD. Additionally, autoimmunity immune dysfunction, and neuroinflammation are also
considered as etiological mechanisms of this disorder. This study aimed to elucidate the relationship between
glutamatergic/ GABAergic imbalance and neuroinflammation as two recently-discovered autism-related etiological
mechanisms.
Methods: Twenty autistic patients aged 3 to 15 years and 19 age- and gender-matched healthy controls were
included in this study. The plasma levels of glutamate, GABA and glutamate/GABA ratio as markers of excitotoxicity
together with TNF-α, IL-6, IFN-γ and IFI16 as markers of neuroinflammation were determined in both groups.
Results: Autistic patients exhibited glutamate excitotoxicity based on a much higher glutamate concentration in
the autistic patients than in the control subjects. Unexpectedly higher GABA and lower glutamate/GABA levels were
recorded in autistic patients compared to control subjects. TNF-α and IL-6 were significantly lower, whereas IFN-γ
and IFI16 were remarkably higher in the autistic patients than in the control subjects.
Conclusion: Multiple regression analysis revealed associations between reduced GABA level, neuroinflammation
and glutamate excitotoxicity. This study indicates that autism is a developmental synaptic disorder showing
imbalance in GABAergic and glutamatergic synapses as a consequence of neuroinflammation.
Keywords: Autism, Glutamate excitotoxicity, Gamma aminobutyric acid (GABA), Glutamate/GABA, Tumor necrosis
factor-α, Interleukin-6, Interferon-gamma, Interferon-gamma-inducible protein 16Introduction
The brain’s immune system is controlled by the microglia,
a set of cells that when activated can secrete numerous
cytokines, chemokines, eicosanoids, proteases, complement
and excitotoxins [1]. It is well known that microglial
immune cytokines can be activated by, heavy metals
(for example, mercury), amyloid, bacteria, and glutamate.
During neurodevelopment, the immune cytokines can act
as neurotrophic substances, protecting and promoting
neurite growth. With excess activation and when chronic-
ally activated, these cytokines can be very destructive.* Correspondence: elansary@ksu.edu.sa
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unless otherwise stated.An autotoxic, non-specific immune destruction of neu-
rons, neurites and synaptic connections has been described
by McGeer et al. [2]. In this process, either systemic im-
mune factors (cytokines) or local immune factors, such as
beta-amyloidcan activate the brain’s immune system via
activation of astrocytes and microglia. In both instances
brain levels of cytokines, reactive oxygen and nitrogen
species, cellular immune components, excitotoxins and
arachidonic acid are elevated leading to brain dysfunction.
The difference in severity between patients with autism
appears to vary with the stage at which the immune/exci-
totoxic stress arises and its intensity. In humans, it is well
known that a considerable amount of postnatal brain
development occurs, with the highest synaptogenesis
occurring during the last trimester and the first twoed Central Ltd. This is an Open Access article distributed under the terms of the
reativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution,
he original work is properly credited. The Creative Commons Public Domain
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can interfere with neuronal migration patterns, differen-
tiation and synaptic development, resulting in varying
degrees of abnormal brain architecture and hence dif-
fering severities of autistic features.
Glutamate exerts its effect through metabotropic
(mGlu) and ionotropic (iGlu) glutamate receptors lo-
calized in the cellular membranes of neurons and glia
as neuron-supporting cells. According to their differential
affinity for different agonists, ionotropic receptors include
N-methyl-D-aspartate (NMDA), kainate (KA), and amino-
3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA)
[3]. The metabotropic receptors belong to the G-protein-
coupled receptor, and can be divided into group I
(mGluR1 and mGluR5), group II (mGluR2 and mGluR3)
and group III (mGluR4 and mGluR6-8) according to their
primary sequence and pharmacological agonists [4]. The
increased probability of epilepsy in patients with autism
suggests enhanced glutamatergic signaling with positive
correlation between plasma levels of glutamate and the
severity of autism and increased expression of mRNAs
encoding the AMPA 1 receptor in the cerebellum of
autistic patients [5,6].
While in the adult brain gamma aminobutyric acid
(GABA) acts as an inhibitory neurotransmitter, during
the perinatal period it depolarizes targeted cells and trig-
gers calcium influx. GABA-mediated calcium signaling
regulates a number of important developmental pro-
cesses which include, cell proliferation, differentiation,
synapse maturation, and cell death [7]. A dysfunction of
the GABAergic signaling early in development leads to a
severe excitatory/inhibitory (E/I) imbalance in neuronal
circuits, a condition that may account for some of the
behavioral deficits observed in patients with autism [8].
The GABA level, glutamate/GABA and glutamine/glu-
tamate ratios are significantly lower in patients with aut-
ism compared to normal controls, thus suggesting a
possible abnormality in the regulation between GABA
and glutamate that might lead to excitotoxicity [9,10].
The overall aim of this study is to confirm that GABA
and glutamate synapses are abnormal in autistic pa-
tients and to determine how these abnormalities may be
associated with one another and with neuroinflamma-




The study protocol followed the ethical guidelines of the
most recent Declaration of Helsinki (Edinburgh, 2000). All
subjects enrolled in the study (20 autistic male patients
and 19 age- and gender-matched controls) had written
informed consent provided by their parents and assented
to participate if developmentally able. They were enrolledthrough the ART Center (Autism Research & Treatment
Center) clinic (Riyadh, Saudi Arabia). The ART Center
clinic sample population consisted of children diagnosed
on the ASD. The diagnosis of ASD was confirmed in all
subjects using the Autism Diagnostic Interview-Revised
(ADI-R) and the Autism Diagnostic Observation Schedule
(ADOS) and 3DI (Developmental, Dimensional Diagnostic
Interview). The ages of all autistic children who partici-
pated were between 4 and 12 years old. All were simplex
cases. All were negative for fragile X gene study. The con-
trol group recruited from Well-baby Clinic at King Khaled
University hospital with mean age of 4 to 11 years. Sub-
jects were excluded from the investigation if they had
organic aciduria, dysmorphic features, or diagnosis of
fragile X or other serious neurological (for example,
seizures), psychiatric (for example, bipolar disorder)
or known medical conditions. All participants were
screened via parental interview for current and past
physical illness. Children with known endocrine, car-
diovascular, pulmonary, liver, kidney or other medical
diseases were excluded from the study. None of the re-
cruited autistic patients were on special diets or taking
alternative treatments.
Ethics approval and consent
A written consent was obtained from the parents of each
individual case, according to the guidelines of the ethical
committee of King Khalid Hospital, King Saud University.
Blood samples
After an overnight fast, 10 ml blood samples were collected
from both groups in test tubes containing sodium heparin
as anticoagulant. Tubes were centrifuged at 3,500 rpm at
room temperature for 15 minutes; plasma was obtained
and deep frozen (at −80°C) until analysis.
Determination of GABA
The quantitative determination of GABA in human
plasma was measured using an ELISA diagnostic kit, a
product of Immunodiagnostic AG, Dusseldorf, Germany.
This assay was based on the method of competitive
ELISAs. The sample preparation included the addition
of a derivatization reagent for GABA. Afterwards, the
treated samples were incubated in wells of a microtiter
plate coated with a polyclonal antibody against the
GABA derivative, together with an assay reagent con-
taining a GABA-derivative (tracer). During the incuba-
tion period, the target GABA in the sample competed
with the tracer for the binding of the polyclonal anti-
bodies on the wall of the microtiter wells. GABA in the
sample displaced the tracer from binding to the anti-
bodies. Therefore, the concentration of antibody-bound
tracer was inversely proportional to the GABA concentra-
tion in the sample. A dose-response curve of absorbance
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generated using the values obtained from the standards.
GABA present in the patient samples (EDTA plasma) was
determined directly from this curve.
Measurement of glutamate
Glutamate level was assessed using an HPLC method [11].
Plasma samples (0.1 ml) were mixed with 5 μl of mercap-
toethanol and allowed to stand for 5 minutes at room
temperature, then precipitated with ice-cold methanol
while being vortexed. Tubes were allowed to stand for
15 minutes in an ice bucket before samples were separated
by centrifugation (5,000 rpm for 15 minutes) and the
supernatant was collected. The efficiency of the protein
precipitation step was assessed by Bradford’s dye-binding
method [12]. The protein-free supernatants were proc-
essed immediately for HPLC analysis of glutamate.
Assay of TNF-α
TNF-α was measured using a mouse TNF-α ELISA kit
(Hycult Biotech, Uden, Netherlands. The antibody reacts
with the natural TNF-α of the rats and identifies
membrane- as well as receptor-bound TNF-α. The TNF-
α trimer interacts with either of the two types of TNF-R,
leading to receptor cross-linking. One unit of Hycult
Biotech Mouse TNF-α approximates the bioactivity of
16 units of human TNF-α according to the standard
L929 cytotoxicity assays for TNF-α prepared by the
World Health Organization (WHO).
Assay of IL-6
IL-6 was assayed using a Quantikine ELISA kit (R&D
Systems, Minneapolis, MN, USA). A microplate was pre-
coated with a monoclonal antibody specific for rat IL-6.
Fifty microliters of each standard, control, or sample
were placed in separate wells. The reagent was mixed by
gently tapping the plate frame for 1 minute after being
covered with the adhesive strip provided. The plate was
incubated for 2 hours at room temperature and any rat
IL-6 present was bound by the immobilized antibody.
After washing away unbound substances, an enzyme-
linked polyclonal antibody specific for rat IL-6 was
added to the wells. Following a subsequent wash step to
remove unbound antibody-enzyme reagents, 100 μl of
substrate solution was added to each well and the plate
was incubated for 30 minutes at room temperature. The
enzyme reaction yielded a blue product that turned yel-
low when the stop solution was added. The intensity
measured for the color was in proportion to the amount
of rat IL-6 bound in the initial step.
Assay of IFN-γ
IFN-γ was measured using an ELISA kit, a product of
Thermo Scientific (Rockford, IL, USA) [13] according tothe manufacturer’s instructions. This assay employs a
quantitative sandwich enzyme immunoassay technique
that measures IFN-γ in less than 5 hours. The minimum
level of rat IFN-γ detected by this product was less than
2 pg/ml read off the standard curve.
Determination of interferon-γ-inducible protein 16 (IFI16)
The human IFI16 ELISA kit was provided by Bio-
Source2 Kallang Avenue, 06-32, Singapore 339407. This
immunoassay kit allows for the in vitro quantitative de-
termination of human IFI16 concentrations in plasma.
The IFI16 ELISA kit applied the quantitative sandwich
enzyme immunoassay technique. The microtiter plate
had been pre-coated with a monoclonal antibody spe-
cific for IFI16. Standards or samples were then added to
the microtiter plate wells and IFI16, if present, bound to
the antibody precoated wells. In order to quantitatively
determine the amount of IFI16 present in the sample,
a standardized preparation of horseradish peroxidase
(HRP)-conjugated polyclonal antibody, specific for IFI16,
was added to each well to ‘sandwich’ the IFI16 immobi-
lized on the plate. The microtiter plate then underwent
incubation, and the wells were subsequently thoroughly
washed to remove all unbound components. Next, sub-
strate solutions were added to each well. The enzyme
HRP and substrate were allowed to react over a short
incubation period. Only those wells that contained IFI16
and HRP-conjugated antibody exhibited a change in
color. The enzyme-substrate reaction was terminated by
the addition of a sulfuric acid solution and the color
change was measured spectrophotometrically at a wave-
length of 450 nm. A standard curve was plotted relating
the intensity of the color (optical density) to the concen-
tration of standards. The IFI16 concentration in each
sample was interpolated from this standard curve.
Results
Levels of glutamate, GABA, glutamate/GABA, TNF-α, IL-
6, IFN-γ and IFI16 were compared between patients with
autism and age-matched control subjects. Data are pre-
sented as a mean ± SD of a number of 20 patients with
ASD compared to 19 controls, and the significant differ-
ence between both groups was presented in Table 1. It
was noticed that the six measured parameters differed sig-
nificantly between patients and controls. Figures 1, 2 and
3 demonstrate individual data distribution around the
mean value represented as a straight line for the stud-
ied parameters. Table 1 also represents the percentage
increase or decrease of the measured parameters of
autistic patients relative to control subjects. It can be
easily observed that GABA and glutamate recorded 57
and 36% increase respectively in autistic compared to
control subjects and about 13% decrease in glutamate/
GABA ratio. Table 1 also shows about 25% decrease in
Table 1 Levels of the measured parameters in plasma of autistic patients compared to control
Parameter Group N Mean ± SD Percent change P-value
GABA (μmol/l) Control 19 0.53 ± 0.05 100.00 0.001
Autistic 20 0.83 ± 0.12 157.71
Glutamate (μmol/l) Control 19 111.91 ± 4.63 100.00 0.001
Autistic 20 152.80 ± 6.47 136.54
Glutamate/GABA ratio Control 19 214.72 ± 22.26 100.00 0.003
Autistic 20 188.12 ± 30.11 87.61
IL-6 Control 19 363.49 ± 22.88 100.00 0.001
Autistic 20 273.87 ± 32.49 75.34
TNF-α Control 19 346.23 ± 24.95 100.00 0.001
Autistic 20 252.35 ± 63.60 72.89
INF-γ (ng/ml) Control 19 50.85 ± 5.71 100.00 0.001
Autistic 20 85.33 ± 9.06 167.80
IFI16 (ng/ml) Control 19 1.91 ± 0.60 100.00 0.001
Autistic 20 3.11 ± 1.01 162.49
Table 1 describes the independent samples t-test between the control and autistic groups for all parameters.
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and IFI16 respectively.
Table 2 and Figure 4 (a-d) demonstrate the receiver op-
erating characteristics (ROC) analysis data as area under
the curve (AUC), cutoff values, specificity, and sensitivity
of the measured parameters. All parameters exhibited
AUC values close to 1 and satisfactory values of accuracy
presented as high specificity and sensitivity.
Tables 3, 4 and 5 demonstrate the multiple regression
analysis between the measured parameters using GABA,
glutamate and glutamate/GABA as dependent variables
respectively.
Discussion
GABA and glutamate are the main inhibitory and exci-
tatory neurotransmitters in the human brain. Both haveFigure 1 Gamma aminobutyric acid (GABA) (μmol/l), glutamate (μmo
The mean value for each group is designated by a line.critical roles during early development of the nervous
system, a stage when clinical presentation indicates that
autism begins. Therefore, it is important to understand
the functional status of GABAergic and glutamatergic
neurotransmission in the plasma as the body fluid reflects
brain physiology and pathology. Clarification of the rela-
tionship between abnormality in the absolute and relative
GABAergic and glutamatergic synaptic activities and neu-
roinflammatory biomarkers represented by TNF-α, IL-6,
IFN-γ, and IFI16 could help to find a target for pharmaco-
logical intervention.
Brain GABA and glutamate metabolism include a series
of integrated and interconverted pathways. Glutamate, in
addition to its importance in the clearance of brain
ammonia through glutamine synthesis, serves as an im-
portant energy source through the tricarboxylic acid cyclel/l) and glutamate/GABA ratio in control and autistic patients.
Figure 2 IL-6 and TNF-α in control and autistic patients. The mean value for each group is designated by a line.
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genase and oxidative decarboxylation by α-ketoglutarate
dehydrogenase. Glutamate is converted to GABA by
glutamic acid decarboxylase. Finally, GABA is metabo-
lized to succinate by the combined reactions of GABA
transaminase and succinic semialdehyde dehydrogen-
ase. The significant increase of the absolute concentra-
tion of both neurotransmitters reported in the present
study, together with the remarkable decrease in the glu-
tamate/GABA ratio in autistic patients compared to
healthy controls (Table 1), can be easily related to autis-
tic characteristics. Since GABA derives from glutamate
and glutamate derives from GABA, alterations in both
neurotransmitters can affect each other. The unex-
pected elevation of GABA as an inhibitory neurotrans-
mitter in autistic patients with a high rate of onset of
epilepsy could be explained on the basis that high
plasma GABA could be concomitant with lower brain
GABA due to a smaller number or dysfunctional neuronal
GABA receptors. GABA exerts its functions by binding toFigure 3 INF-γ (ng/ml) and IFI16 (ng/ml) in control and autistic patienchloride-permeable ionotropic GABAA receptors and
metabotropic GABAB receptors. This explanation can
be acceptable because GABAergic transmission through
receptors is achieved by different mechanisms such as
modulation of GABAA receptors and variation of intra-
cellular chloride concentration together with alteration
in GABA concentration [14]. Elevation of GABA level,
which was recorded in the present study, can be easily
related to the significant elevation of glutamate as sub-
strate of glutamate decarboxylase. The suggested role
of GABA receptors in the excitotoxicity or inhibitory/
excitatory imbalance in autistic patient could be sup-
ported through the recent work of Han et al. [15] in
which low doses of benzodiazepines increase inhibitory
neurotransmission through positive allosteric modulation
of post-synaptic GABAA receptors, improved impaired
social interaction, repetitive behavior, and cognitive ability
in an animal model of autism. In contrast, negative allo-
steric modulation of GABAA receptors impaired social
behavior in wild-type mice, supporting the notion thatts. The mean value for each group is designated by a line.
Table 2 Receiver operating characteristics (ROC) curve of all parameters in autistic groups
Area under the curve Best cutoff value Sensitivity % Specificity %
GABA (μmol/l) 1.000 0.617 100.0% 100.0%
Glutamate (μmol/l) 1.000 131.110 100.0% 100.0%
Glutamate/GABA ratio 0.787 191.792 75.0% 84.2%
IL-6 0.984 333.840 95.0% 94.7%
TNF-α 0.903 285.530 80.0% 100.0%
INF-γ (ng/ml) 1.000 62.780 100.0% 100.0%
IFI16 (ng/ml) 0.864 1.860 100.0% 63.2%
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social and cognitive deficits as autistic characteristics.
The recorded decrease of IL-6 and TNF-α in plasma of
autistic patients compared to control healthy participants
(Table 1) could be a consequence of an early elevation of
these cytokines in plasma followed by influx of both to the
brain across the blood-brain barrier (BBB). This explan-
ation can be supported by many studies that proved the
elevation of IL-6 in autistic brains [16]. AlthoughFigure 4 Receiver operating characteristics curve (ROC) curve of: (a) g
(b) glutamate/GABA ratio, (c) and (d) INF-γ (ng/ml) and IFI16 (ng/ml) in auelevation of IL-6 is a repeated finding in autism, the
exact mechanism by which an IL-6 increase may con-
tribute to the pathogenesis of this disorder remains un-
defined. The association between IL-6 and low glutamate/
GABA ratio (Table 5) observed in the present study, could
help in clarifying this mechanism. Firstly, a key role for in-
hibitory/excitatory imbalance in autism is supported by
the fact that 10 to 30% of autistic patients suffer from epi-
lepsy [17]. This synaptic abnormality hypothesis wasamma aminobutyric acid (GABA; μmol/l) and glutamate (μmol/l),
tistic groups.
Table 3 Multiple regression using stepwise method for




Beta P-value Adjusted 2R Model
F-value P-value




Table 5 Multiple regression using stepwise method for




Beta P-value Adjusted 2R Model
F-value P-value
GABA (μmol/l) −1.545 0.001 0.935 183.521 0.001
Glutamate (μmol/l) 1.049 0.001
IL-6 0.157 0.036
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ing synaptic cell adhesion molecules, as well as synaptic
proteins in autistic subjects [18-20]. Secondly, IL-6 ele-
vation was found to stimulate excitatory synapse forma-
tion and impair the development of inhibitory synapses.
This role of IL-6 was supported by the detection of a re-
duced post-excitatory inhibition in IL-6 overexpressed
mice. Post-excitatory inhibition, which is usually mea-
sured by paired-pulse inhibition (PPI) has been sug-
gested as being caused by a reduction in the release of
glutamate from terminals of afferent axons [21,22]. This
effect seems to be the result of an inhibition of calcium
influx through presynaptic receptors, which play a crit-
ical role in the release of glutamate from synaptic vesi-
cles on afferent stimulation [23,24]. Thirdly, mice with
elevated IL-6 in the brain display many autistic features,
including impaired cognitive abilities, deficits in learn-
ing, abnormal anxiety traits and habituations, as well as
decreased social interactions [13].
The suggested increase of brain TNF-α and the associ-
ation between this cytokine and the impaired glutamate/
GABA ratio reported in the present study (Table 5)
could be explained on the basis of the interesting rela-
tionship between neurons, glial cells and TNF-α leading
to glutamate excitotoxicity [25]. In general, excitotoxicity
is related to the activation of NMDA receptors by exces-
sive glutamate. Brain cell death usually occurs after over
stimulation of glutamate receptors due to impaired re-
uptake of glutamate by the EAAT2/GLT-1 transporters
on glial cells [26]. The expression of this transporter has
been shown to be regulated by NF-κB [27]. Pickering
et al. [28] showed that increased levels of TNF-α might
be easily related to glutamate excitotoxicity through the
decrease of EAAT2/GLT-1 expression. TNF-α induces
the classical I kappa B (IκB) degradation pathway toTable 4 Multiple regression using stepwise method for
glutamate (μmol/l) as a dependent variable
Predictor
variable
Beta P-value Adjusted 2R Model
F-value P-value
INF-γ (ng/ml) 0.594 0.001 0.869 85.107 0.001
TNF-α −0.238 0.003
IL-6 −0.221 0.026trigger NF-κB nuclear translocation and DNA binding to
repress EAAT2 expression. In this situation, the pres-
ence of elevated TNF-α concentrations leads to elevated
extracellular glutamate concentration, thereby increasing
the risk of glutamate excitotoxicity. Elevated TNF-α
concentrations could be also contributed to the decrease
of the inhibitory transmission. Recently, an in vitro
culture study in mature rat and mouse hippocampal
neurons demonstrated that acute (45 minute) applica-
tion of TNF-α induced a rapid and persistent decrease
of inhibitory synaptic strength as well as a downregula-
tion of cell-surface levels of GABAA receptors [29].
Table 1 demonstrates the large significant increase of
IFN-γ in plasma of autistic patients compared to healthy
control participants. This increase was associated with
the low glutamate/GABA ratio representing inhibitory/
excitatory synaptic transmission (Table 5). This associ-
ation could be reasonably accepted and explained on the
basis of the key role of IFN-γ in the induction of neuro-
toxicity. Recently, it has been proposed that IFN-γ directly
induces neuronal dysfunction through the formation
of dendritic beads in mouse cortical neurons and the
enhancement of glutamate neurotoxicity via AMPA but
not NMDA receptors. IFN-γ forms a unique, neuron-
specific, calcium-permeable receptor complex with AMPA
receptor subunit GluR1. Through this receptor complex,
IFN-γ phosphorylates GluR1 at serine 845 position by
the JAK1-2/STAT1 pathway, increases Ca+2 influx and
nitric oxide production, and subsequently decreases
ATP production, leading to the dendritic bead forma-
tion. This explanation could provide a mechanisms
through which inflammation could be related to glutamate
excitotoxicity as an etiological signaling involved in autism
pathology [30].
ROC analyses of glutamate, GABA, glutamate/GABA,
TNF-α, IL-6, IFN-γ and IFI16 are presented in Table 2
and Figures 4 (a-d). All measured parameters demonstrated
satisfactory sensitivity and very high specificity, which con-
firmed the hypothesis that autistic patients are character-
ized by excitotoxicity and suffer from neuroinflammation.
Multiple regression analysis, as one of the most power-
ful methods of data analysis, was used between the
measured parameters to determine the relative con-
tribution of impaired GABAergic and glutamatergic
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and to predict the role of the measured cytokines in the
glutamatergic/GABAergic imbalance in autistic patients
compared to healthy control subjects (Tables 3, 4 and 5).
The finding that the high plasma GABA levels are
positively correlated to glutamate and glutamate/GABA
levels (Table 3) led us to propose that the unexpected
increase in GABA concentration in autistic patients is
induced partly by glutamate bioavailability as substrate to
glutamate decarboxylase (GAD) enzyme. This can be sup-
ported by the value of R2, which shows that 0.973 or 97%
of the variance in GABA was related to the elevation of
glutamate. Despite the elevated GABA in plasma of autis-
tic patients, a dysfunction in inhibitory GABAergic trans-
mission is suggested due to a reduced density of GABAA
receptors in the hippocampus [31,32], reduced GABAA
and GABAB receptor protein subunits in the cerebellum,
prefrontal Brodmann area 9 and parietal Brodmann area
40 [33,34], and a reduced expression of the GABA-
synthesizing iso-enzymes GAD65 and GAD67 in the
parietal and cerebellar cortices in autistic brains [35].
Table 4 demonstrates the stepwise multiple regression
analysis using glutamate as dependent variable and
TNF-α, IL-6, IFN-γ and IFI16 as independent variables.
The value of R2 shows that 0.869 or almost 87% of the
variance in glutamate was explained by, or related to,
neuroinflammation as discussed above. While, IFN-γ
cytokine was the most significantly related to glutamate
excitotoxicity, IFI16 did not contribute.Conclusion
Based on the present study, it could be concluded that
glutamate/GABA balance or excitatory/inhibitory balance
is crucial for the functioning of the synapse. Multiple
mechanisms may compromise this balance; neuroinflam-
mation highly contributes to the imbalance and conse-
quently to the etiology of autism.
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